Clinical Trials · NCT02057172
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Enrollment
- 254
- Start date
- Jan 2014
- Locations
- 1 site, United States
- Primary endpoint
- Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks